Researchers have announced results from a large clinical trial testing a new personalised cancer vaccine administered alongside an established immunotherapy drug. The combination reduced the risk of melanoma patients experiencing disease recurrence or death by 42% compared to immunotherapy treatment alone. Additionally, the vaccine reduced the risk of melanoma spreading over a two-year period by 38%.
The trial enrolled 1,137 adults who received Keytruda, a widely used immunotherapy medication that enhances the body’s immune response against cancer cells. Approximately two-thirds of participants also received Intismeran, an experimental vaccine based on mRNA technology, while the remaining participants received a placebo. The vaccine was personalised for each patient using genetic information from their own tumour to help train their immune system to recognise and target cancer cells.
Manufacturers MSD and Moderna indicate they are pursuing regulatory approval and may file with health authorities as soon as next year. The companies are also testing the same approach against other cancer types including kidney, bladder, and lung cancer. Stock prices for both companies have increased since the initial announcement, though some analysts noted the results fell slightly short of expectations from a smaller earlier trial.
Independent oncologists praised the results as noteworthy but cautioned that longer-term follow-up studies are necessary to demonstrate whether the treatment meaningfully extends overall survival. Researchers note that broader adoption within healthcare systems will also depend on cost considerations, given that each patient requires individual tumour analysis and customised vaccine production. The trial will continue monitoring participants to assess long-term outcomes and overall survival benefits.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI